New polymorphic short tandem repeats for PCR-based Charcot-Marie-Tooth disease type 1A duplication diagnosis.

BACKGROUND Charcot-Marie-Tooth disease type 1A (CMT1A) accounts for 70-90% of cases of CMT1 and is most frequently caused by the tandem duplication of a 1.4-Mb genomic fragment on chromosome 17p12. Molecular diagnosis of CMT1A has been based primarily on pulsed-field electrophoresis, fluorescence in situ hybridization, polymorphic allele dosage analysis, and quantitative PCR. We sought to improve the fidelity and applicability of PCR-based diagnosis by developing a panel of novel, highly polymorphic short tandem repeats (STRs) from within the CMT1A duplicated region. METHODS We used a recently available genomic sequence to identify potentially polymorphic simple repeats. We then amplified these sequences in a multiethnic cohort of unaffected individuals and assessed the heterozygosity and number of alleles for each STR. Highly informative markers were then tested in a set of previously diagnosed CMT1A duplication patients, and the ability to identify the genomic duplication through the presence of three bands was assessed. RESULTS We identified 34 polymorphic markers, 15 of which were suitable for CMT1A diagnosis on the basis of high heterozygosity in different ethnic groups, peak uniformity, and a large number of alleles. On the basis of the fluorescent dye and allele range of each marker, we developed two panels, each of which could be analyzed concurrently. Panel 1, which comprised 10 markers, detected 37 of 39 duplications, whereas panel 2, which comprised the remaining 5 markers, identified 21 of 39 duplications. Through the combination of both panels, we identified 39 of 39 duplications in previously diagnosed CMT1A patients. CONCLUSIONS The newly developed 15-marker set has the capability of detecting > 99% of duplications and thus is a powerful and versatile diagnostic tool.

[1]  B. Birren,et al.  The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. , 2001, Genome research.

[2]  Á. Carracedo,et al.  Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions. , 2000, Clinical chemistry.

[3]  J. Lupski,et al.  Delineation of the critical interval of Bardet-Biedl syndrome 1 (BBS1) to a small region of 11q13, through linkage and haplotype analysis of 91 pedigrees. , 1999, American journal of human genetics.

[4]  J. Lupski,et al.  Molecular Mechanisms for CMT1A Duplication and HNPP Deletion , 1999, Annals of the New York Academy of Sciences.

[5]  L. Shaffer,et al.  Prenatal diagnosis of Charcot–Marie–Tooth disease type 1A by interphase fluorescence in situ hybridization , 1999, Prenatal diagnosis.

[6]  J. Lupski,et al.  Molecular mechanisms for CMT1A duplication and HNPP deletion. , 1999, Annals of the New York Academy of Sciences.

[7]  C. van Broeckhoven,et al.  Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies. , 1999, Journal of the peripheral nervous system : JPNS.

[8]  G. Nicholson,et al.  Determination of gene dosage at the PMP22 and androgen receptor loci by quantitative PCR. , 1998, Clinical chemistry.

[9]  E. Ringelstein,et al.  PCR-based strategy for the diagnosis of hereditary neuropathy with liability to pressure palsies and Charcot-Marie-Tooth disease type 1A , 1998, Neurology.

[10]  A. Brice,et al.  Sex–dependent rearrangements resulting in CMT1A and HNPP , 1997, Nature Genetics.

[11]  J. Lupski,et al.  The human COX10 gene is disrupted during homologous recombination between the 24 kb proximal and distal CMT1A-REPs. , 1997, Human molecular genetics.

[12]  J. Lupski.  Charcot-Marie-Tooth disease: a gene-dosage effect. , 1997, Hospital practice.

[13]  L. Shaffer,et al.  Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. , 1997, American journal of medical genetics.

[14]  J. Lupski.  DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies. , 1996, Clinical chemistry.

[15]  I. Blair,et al.  Detection of Charcot-Marie-Tooth type 1A duplication by the polymerase chain reaction. , 1995, Clinical chemistry.

[16]  D. Le Paslier,et al.  Assignment of microsatellite sequences to the region duplicated in CMT1A (17p12): a useful tool for diagnosis. , 1995, Journal of medical genetics.

[17]  J. Lupski,et al.  Two autosomal dominant neuropathies result from reciprocal DNA duplication/deletion of a region on chromosome 17. , 1994, Human molecular genetics.

[18]  J. Lupski,et al.  Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. , 1993, American journal of human genetics.

[19]  A. C. Chinault,et al.  Charcot–Marie–Tooth type 1A duplication appears to arise from recombination at repeat sequences flanking the 1.5 Mb monomer unit , 1992, Nature Genetics.

[20]  F. Baas,et al.  Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a) , 1991, Neuromuscular Disorders.

[21]  Aravinda Chakravarti,et al.  DNA duplication associated with Charcot-Marie-Tooth disease type 1A , 1991, Cell.

[22]  H. Skre,et al.  Genetic and clinical aspects of Charcot‐Marie‐Tooth's disease , 1974, Clinical genetics.

[23]  D. Seligson,et al.  Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.